atepeq/tico19 huggingface dataset:
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
Mpo na basali ya sante bazo kengela bato ya bokono ya COVID-19, CDC azo tinda botie ya moto na Disuku ya Bokabolami ya infection Ebotamaka na Mopepe (AIIR) na bobakisi ya ba precaution standarde, baprecauton ya contacki pe baprecaution ya mopepe. CDC apesi masungi mpóna bosaleli ya bisaleli ya bobateli ya moto yemoko (PPE) na ntango ya pandemi.
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
Materiel bazo tinda osalela eza:: Elamba ya PPE, respirateur to masike ya elongi, libateli ya miso, pe bagan ya monganga.Tango ekozala, ba respirateur (na esika ya bizipeli ya elongi) elingama koleka.
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
Ba respirateur N95 endimami mpóna bisika ya industrie, kasi FDA asi apesi ndíngisa mpóna bosaleli ya ba masike ose ya Ndingisa ya Bosáleli na Bombángo (EUA).
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
Esi ebongisama mpóna kobatela moto na pusiele ezalaka na mopepe kasi bolamo nayango na bokati ya bolekisi ya mikolobe eza garanti te na bosaleli na yango.
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
Ntango bamasike eza te, CDC etindi bosaleli ya ba pareface to, na bozangi nionso, masike esalami na ndako.
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
Ba cas ngambo ya nyonso ya COVID-19 eza nango songe molai te mpo esenga bosaleli ya mopepe ya masini to ba alternatifi, kasi pourcent ya ba cas ezo senga yango.
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
Type ya soutien ya pema mpóna bato ya pasi ekangami na kopola ya pema ya COVID-19 ezo yekolama makasi mpóna bato baza na lopitalo, na elembo ete botie na tiyo eko kokima na bolekisi mopepe makasi na cannule na nzela ya pema to na pression positive ya nivo mibale.
Whether either of these two leads to the same benefit for people who are critically ill is not known.
Kasi eyebani te soki ta moko ya bango mibale ezo mema babenefice ya ndenge moko mpóna bato bazo bela makasi.
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
Minganga mosusu bazo mpóna masini ya mopepe ya kati ya nzoto soki ezali na ntina ete tekiniki óyo epekisaka bopalangani ya biteni mike-mike na mopepe mutu esalamka na bosaleli ya cannule ya mopepe ya makasi na zolo. Ba cas makasi emonanaka mingi na bato bakolo (baye baleki mibu 60, pe mingi-mingi penza baye baleki mibu 80).
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
Bikolo mingi ya dévelopé bizangi ba mbeto ekoka na lopitalo mpóna moto moko-moko, yango nde etie ndelo na systemi ya sante mpóna koyamba na bombango nomba ya bacas ya COVID-19 ya songe ekoka mpo bakota lopitalo.
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
Liyekoli moko na Chine emonaki ete na 5% ya bato bayambaki na ba unité ya soin intensif, 2.3% bazalaki ose ya bosaliseli ya masini ya mopepe, pe 1.4% bakufaki.
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
Na Chine, ngambo ya 30% ya bato bakotaka lopitalo mpóna COVID-19 basukelaka koyambama na USI.
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
Bopési mopepe na masini ekomi compliqué mingi mpóna pasi ya syndrome ya songe ya kopema (ARDS) ezo kola na COVID-19 pe bopesi oxygene ezo koma penza pasi mingi .
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
Ba ventilateur óyo eza na mode eko kocontrolé pression na PEEP ya likolo ezo lingama mpóna ko maximisé bopesi ya oxygene elongo na bokitisi ya likama ya bozoki ya lipili ewutaka na mopepe pe panzi ya tolo.
High PEEP may not be available on older ventilators.
PEEP ya makasi eko kozanga na baventilateur ya kala.
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
Boluki na batraitement eko kosalisa ebandaki na Janvier 2020, pe bakisi ya antivirusi ebele ezo mekama na cliniki.
Remdesivir appears to be the most promising.
Remdesivir ezo monana na elaka mingi koleka nionso.
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
Ata ko bakisi ya sika eko kozwa ti 2021 mpóna kokomelisa, ebele ya bakisi bazali kotesité esi endimami mpóna kosalela na makono mosusu to ekomi mosika mpóna batesite.
Antiviral medication may be tried in people with severe disease.
Bakisi ya antivirusi eko komekama na nzoto ya bato baza na bokono makasi.
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
OMS azo tinda bato ya bolingi bakota na momekano mpóna bolamo na kimia ya bisaleli ya bakísi ezo bongisama. FDA asi apesi ndíngisa ya mikolo mokuse na plasma ya babiki likolo ya lisalisi ya momekano na bacas óyo emonani bomoi ya moto eza somo to elingi solo kokatana noki-noki.
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
Ezwi naino boyekoli ya cliniki elingami te mpóna kolakisa ete ezali ya kimia pe malamu mpóna kosukisa bokono.
In February 2020, China launched a mobile app to deal with the disease outbreak.
Na Février 2020, Chine abimisaki app ya mobile mpóna koluka kosilisa pandemie.
Users are asked to enter their name and ID number.
Basaleli basengami batia kombo pe numero ya ID nabango.
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
App eza na mambi ya koyeba ‘contacki ya ngambo’ na bosaleli ya badonnée ya bokengeli ebongo nde likama eko koya mpóna kpokoso.
Every user can also check the status of three other users.
Mosaleli moko-moko akoki pe kovérifié etat ya basaleli mosusu misato.
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
Soki likama ezo ya ekoki komonana, app ekotinda kaka moto amitia na quarantaine te kasi lisusu ekoyebisa bakonzi ya santé ya esika.Badonnée minene ya bososoli na fonimobile, tekinologi ya boyebeli elongi, trackage ya ba fonimobile, na mayele ya bonganga bizali kosalamela mpóna kotracké bato ya kpokoso bazo sala contacki na Korea ya Sudi, Taiwan pe Singapore.
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
Na Mars 2020, loyalo ya Israeli apesaki ndíngisa na ba agence ya kimia ba tracké badonnée ya bafoni mobile ya bato bakaniselaki bazali na coronavirusi.
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
Mezile wana ezwamakii mpo etia bokasi na quarantaine pe ebatela bato baye bako kozala na contacki na bacitoyen bazali na kpokoso.
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
Lisusu na Mars 2020, Deutsche Telekom akabolaka esika ya badonnée ya bafoni esangana na agence ya federasio ya Alemania, Institut Robert Koch, mpóna kokundola pe kopekisa bopalangani ya virusi.
Russia deployed facial recognition technology to detect quarantine breakers.
Russie abimisaki tekinologi ya boyebeli elongi mpóna koyeba babuki ya quarantaine.
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
Commissaire ya santé regionale ya Italie Giulio Gallera alobaki azwaki liyebisi na ba operateur ya bafoni mobile ete "40% ya bato bazo koba nabango kokendeke bisika".
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
Loyalo ya Alemania asalaki na suka posa moko bangonga 48 ya hackathoni na participant koleka 42.000.
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
Lisusu prezida ya Estonia, Kersti Kaljulaid, asalaki bobengi ya mokili mobimba mpóna koluka mayele ya likolo mpóna kosukisa bopalangani ya coronavirusi.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
Bato moko-moko bako koyoka pasi ya kobungisa elikia na quarantaine, bopekisa ya mibembo, ba effet secondaire ya traitement to kobanga mpóna kpokoso yango.
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC alandi Rory O'Connor na koloba, "bobakisi bokabwani na bato, bofandi moto-na-moto yemoko, kobanga-banga na nzoto pasi, stressi pe kozanga bozwi ezali mbula kake ezo sala mabe na mito ya bato na bolamo nabango."
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
Kobela eko kozwa nzela ya pete na basymptome moke eko kozala kaka lokola bapasi mike-mike ya nzela ya kopema, lokola malili ma bato banso.
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
Ba cas ya pete mingi-mingi esilaka nango sima ya baposo mibale, kasi baye bazalaka na mabela ya pasi mingi ewumelaka banda poso misato ti motoba po esila.
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
Basi ya zemi bako kozala na likama ya makasi mpóna infection ya songe ya COVID-19 ose ya badonnée ya bavirusi óyo ekokana, lokola SRAS pe MERS, kasi badonnée mpóna COVID-19 eza kozanga. Na bato mosusu, COVID-19 eko ko affecté balipili pe panzi.
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
Na baye baza affecté mabe mingi, COVID-19 eko kokoma na bombango syndrome ya songe ya kobela ya pema (ARDS) epesaka kopola ya bopemi, shoki scepitiki to kobeba ya ba organe ebele.
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
Mikakatano ekanganaka na COVID-19 etie nakati sepsis, bokangami ya makila mabe pe bobebi na motema, bangei pe libale.
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
Bokangani ya mabe ya makila, mingi-mingi bomati na ngonga na prothrombine, esi esosolamaki na 6% ya bato baye bandimamaki na lopitalo mpóna COVID-19, kasi kosala ya mabe ya ngei emonani na 4% ya bato ya lisanga.
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
Mokuse ya 20-30% ya bato bazali na COVID-19 balakisi komata ya ba enzyme na ngei (batransaminase).
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
Na bolandi ya lapolo yango kaka, ngonga ya kati banda ebandeli ti bobimi ya basymptome pe liwa ezalaki mikolo zomi, mitano nayango eza na bokoti lopitalo.
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
Bongo, bato babeli batindamaki na USI bazalaki na ngonga ya kati ya mikolo sambo banda bokoti lopitalo ti liwa.
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
Na boyekoli ya bacas ya yambo, ngonga ya kati banda bobimi ya basymtome ya liboso ti liwa ezalaki mikolo 14, na molongo etonda banda motoba ti 41 ya mikolo.
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
Na boyekoli esalami na Commission Nationale ya Santé (NHC) ya Chine, bato-mibali bazalaki na lotango ya bawá ya 2.8% bôngó bato-bâsi bazalaki na 1.7%.
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
Ba exame ya histopathologie ya ba echantillon ya lipili ya mutu ya kokufa elakisi bopanzani ya alveole na ba exudate ya fibromyxoide ya cellula ya mapili nionso mibale.
Viral cytopathic changes were observed in the pneumocytes.
Bambongwana na cytopathiki ya virusi emonanaki na kati ya bapneumocyte.
The lung picture resembled acute respiratory distress syndrome (ARDS).
Foto ya lipili ekokani na pasi ya syndrome ya songe ya pema (ARDS).
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
Na pourcent 11.8% ya bato bakufa basalelaki lapolo na Commission Nationale ya Santé ya Chine, mbeba ya motema emonanaki na banivo emata ya troponine to bokangami ya motema.
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
Na bolandi ya badonnée ya Mars óyo ewutaki na Etats-Unis, 89% ya baye bakotisamaki na lopitalo bazalaki na kobéla liboso. Ba resource ya monganga na ba condisio socio economiki ya engunda eko ko affecté taux ya liwa.
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
Ba estimasio ya lotango ya bato bazalaki kokufa mpóna bokono ekesani na ntina ya mbongwana ya bingunda, kasi pe na ntina ya pasi ya methodologie.
The under-counting of mild cases can cause the mortality rate to be overestimated.
Botangi yase ya bacas ya pete eko kosala ete taux ya liwa ekoma surestimé.
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
Kási, lokola liwa ya bato ewutaki na kobéla bato bazwaki kala, óyo eko koloba ete lotango ya liwa ya mikol’oyo ezali sousetimé.
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
Bameli ya likaya baza na libaku ya 1.4 ya kobéla pasi ya basymtome ya makasi ya COVID-19 pe ngambo 2.4 ya bambala koleka mpóna bosaleli ya soin intensif to kokufa soki bacomparé bango na bato bamelaka likaya te. Kobanga ebimi na bapasi ya mikolo ekolanda bokono.
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
Mokonzi ya Lopitalo ya Hong Kong amonaki bokiti ya 20% ti 30% na makasi ya lipili na bato babikaki na bokono yango, pe ba scanné ya lipili ezo lakisa kobeba ya ba organe.
This may also lead to post-intensive care syndrome following recovery.
Yangó ekoki pe komema lisúsu syndrome ya sima ya intensifi kolanda bobiki.
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
Na Mars 2020, eyebanaki te soki kpokoso eleki eko kopesa immunité ya malamu pe ya ntango molai na bato babikaki na bokono yango.
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
Immunité ezo monana lokola eko kosalama, ose ya bizaleli ya bacoronavirusi mosusu, kasi bacas ya bato babíka na COVID-19 balandamaki na tesite ya positif mpóna coronavirusi na dati ya sima esalameli lapolo.
These cases are believed to be worsening of a lingering infection rather than re-infection.
Ba cas ya boye ezo ndimama ete eza bokiti na ngambo mabe ya bokono ezo sila te kasi kpokoso ya sika te.
The virus is thought to be natural and have an animal origin, through spillover infection.
virusi óyo ezo kaniselama ya mokili pe ebimeli na niama, na bosopani ya infection.
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
Esika ewuti penza eyebani te, kasi nde na Decemba 2019 bopalangani ya kpokoso ezali toloba nionso kokabolama na moto apesi na moto.
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
Liyekoli ya ba cas 41 ya yambo ya COVID-19 endimamaka, ezalaki publié na Janvier 2020 na The Lancet, elobi ete dati basymtome ebandaki liboso ezalaki 1 Decemba 2019.
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
Bapublicasio officielle ya OMS epesi lapolo ete basymtome ya yambo ebandaki na 8 Decemba 2019.
Several measures are commonly used to quantify mortality.
Bamezile ebele ezo salamela mingi mpóna lotango ya bato bóni bazo kufa.
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
Matango maye mazo kesana na bisika mingi mpe na bolandi ntango pe ezo landa monene ya lotango ya batesite, bolamo ya systemi ya santé, ba mpóna ya traitement, ntango ya banda bopalangani ya yambo, pe ya ba characteristiki ya populasio lokola âge, sexe, pe santé mobimba ya moto.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
Na mibu ya suka ya 2019, OMS apesaki na mabela ba code ya bombango ICD-10 ya ba code U07.1 mpóna bawá bawuti na lab-confirmé ya kpokoso ya SARS-CoV-2 pe U07.2 mpóna bawá bawuti na cliniki to diagnostiki ya epidemiologie COVID-19 kozanga ba confirmé yango na lab kpokoso ya SARS-CoV-2. Ratio ya bawá na bacas ezo lakisa lotango ya bawá kokabola na lotango ya bacas basala diagnositiki kati ya intervale ya ntango epesamaki.
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
Na bolandi ba statistiki ya Johns Hopkins University, ratio ya mokili mobimba ya bawá na ba cas ya mabela ezali 6.9% (153,822/2,240,191) uta mokolo ya 17 Avril 2020.
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
Lotango ezo kesana engunda na engunda. Bamezile mosusu etie nakati taux ya bato bazo kufa (CFR), mutu ezo lakisa pourcentage ya bato bazali diagnositiké óyo bazo kufa na bokono, na taux ya koboma ya kpokoso (IFR), mutu ezo lakisa pourcentage ya bato bazwi kpokoso (bazala diagnostiké to diagnostiké te) óyo bazo kufa na bokono.
These statistics are not time bound and follow a specific population from infection through case resolution.
Bastatistiki óyo ekangami na ntango te, ezo landa nde populasio specifiki uta bozwi ya infection ti suka ya cas.
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
Atako bato banso te bazwi kpokoso bazo kolisa ba anticorps, kozala na ba anticorps eko kopesa nsango etali bato boni bakokaki kozwa kpokoso.
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
Na esika ya epicentre ya bopalangani ya bokono na Italie, Castiglione d'Adda, mboka moke ya bato 4600, 80 (1.7%) bawuti kokufa.
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
Na Gangelt, bokono epalanganaki uta bafeti ya Carnavale, pe ekotelaki bana bilenge, ebendaki lotango kamwa moke ya bawei pe nyonso te bato bakufaki na COVID-19 bazalaki classifié ndenge wana .
Furthermore, the German health system has not been overwhelmed.
Na kobakisa, systemi ya Santé ya ba Allemania ezalaki na pasi elekaki ndelo te.
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
Na Netherlanda, ngambo ya 3% bakoki kozala na ba anticorps, lolenge ba evalué bango na bapesi ya makila.
69 (0.004% of the population) have been confirmed to have died from COVID-19.
69 (0.004% ya bato nyonso) bazali kondimama bakufeli na bokono ya COVID-19.
The impact of the pandemic and its mortality rate are different for men and women.
Mabé ya pandemie na lotango ya kobomela bato ekeseni kati ya mibali na bâsi.
Mortality is higher in men in studies conducted in China and Italy.
Taux ya koboma bato babali eleki óyo ya bato bâsi ose ya boyekoli esalami na Chine pe Italie.
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
Likáma ya emati mpóna mibali na mibu 50, bongo bokabwani kati ya mibali na bâsi ezo kangama na ba 90.
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
Na Chine, lotango ya liwa ezalaki 2.8 pourcent mpóna mibali pe 1.7 pourcent mpóna bâsi.
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
Ntina mpóna bokeseni kati ya bâsi na mibali eyebani penza te, kasi eko kozala genetiki na bafacteur ya bizaleli.
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
Bokeseni ya immunologie likolo ya sexe, bosaleli moke ya cigareti na bâsi na mibali na bokolisi ya ba condisio ya bokangani mpóna koboma lokola hypertension ya mibu ya bilenge koleka bâsi eko komatisa lotango likolo na bawá na mibali.
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
Na Europa, 57% ya bato bazwaki kpokoso bazalaki mibali pe 72% ya baye bakufaki na COVID-19 bazalaki mibali.
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Na ntango ti Avril 2020, loyalo ya E.U. azalaki naye kosala lotango na badonnée ya bâsi to mibali ya COVID-19 te.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
Bokundoli elakisi ete bokono ya bavirusi lokola Ebola, HIV, grippe pe SRAS etungisa mibali na basi na bokeseni.
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
Pourcentage emata ya basali ya sante, mingi-mingi ba infirmier, bazali bâsi, ebongo nde baza na lotango ya likama emata mpóna kozala pembeni ya virusi.
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
Organizasio Mondiale mpóna Santé atatolaki na 11 Février 2020 ete kombo ya bokonzi ya bokono yango ekozala "COVID-19".
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
Mokonzi ya OMS Tedros Adhanom Ghebreyesus alimboli ete CO eza mpóna corona, VI mpóna virusi, D mpóna bokono, pe 19 mobu bopalangani eyebani mbala ya yambo: 31 Decemba 2019.
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Kómbó epónama mpóna koboya bolakisi ya mosapi na esika specifiki ya geographi (ndakisa, Chine), esipeci ya niama to lisanga ya bato, na molongo ya mambi matindami na mikili nionso mpóna bopesi kombo bakaniseli ekopekisa stigima. virusi óyo ebendaka COVID-19 ebengami syndrome ya kanda ya songe ya pema coronavirusi 2 (SARS-CoV-2).
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
OMS na kobakisa azo salela "le COVID-19 virusi" pe "le virusi responsable de COVID-19" na bopesi nsango na bato .
Both the disease and virus are commonly referred to as "coronavirus".
Nionso mibale bokono na virusi ezo bengama mingi-mingi kaka "coronavirusi".
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
Na ntango ya bopalangani ya yambo na Wuhan, Chine, virusi na bokono ezalaki nyonso mibale kobengama "coronavirusi" pe "Wuhan coronavirusi".
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
Na Janvier 2020, OMS atindaki bazwa 2019-nCov pe 2019-nCoV bokono ya songe ya pasi ya pema lokola bakombo ya bozeli mpóna virusi pe bokono na bolandi lisungi ya 2015 esika ya boponi bakombo ya bokono pe virusi.
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
Ba nkombo ya bokonzi COVID-19 pe SRAS-CoV-2 ebimaki mokolo ya 11 Février 2020.
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
Ose ya ndelo na ba standard ya molongo ya bobimisi bisaleli monganga, basali mosusu ya biloko ya digitale bazali ko imprimé materiel ya lopitalo lokola batige ya zolo pe ba ndambo ya ventilateur.
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
Na ndakisa moko, ntango lopitalo moko ya Italie ezalaki na posa ya valve ya ventilateur noki-noki, bongo mosali na yango akokaki te kotinda yango na ngonga elingamaki, kompani moko ya esika esalelaki ingénierie inverse pe e imprimaki ba valve 100 balukaki na butu moko.
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Sima ya bopalangani ya yambo ya COVID-19, ba theorie ya complot pe nsango ya lokutá ebimaki na likambo etali esika ya ebandeli, echelle, prevensio, traitement pe makambo mosusu ya bokono epalanganaki mbángo na Interneti.
Humans appear to be capable of spreading the virus to some other animals.
Bato bamonani ete bazali na mambi ma kopalangasa virusi na baniama mosusu.
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
Liyekoli yango elongaki te mpóna komona elembo ya mbotama ya virusi na bangulu, mabata, pe basusu.
No medications or vaccine is approved to treat the disease.
Bakisi to vaccin ta moko te esi endimami mpóna ko traité bokono yango.
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
Bokundoli ya bato ya mikili mingi yase na likambo ya bavaccin na bakísi etali COVID-19 ebandi kosalama ose ya ba organizasio ya loyalo, mangomba ya bato ya mayele pe bakundoli ya industrie.
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
Na Mars, Organisio Mondiale ya Santé ebandaki óyo babengi "Essai ya SOLIDARITE" mpóna koyekola ba effet ya traitement ya b antivirusi composé óyo epesi elikia ya makasi ya lisalisi.
There is no available vaccine, but various agencies are actively developing vaccine candidates.
Vaccin esalami naino te, kasi ba agence ebele bazo tia molende mpóna kokolisa bavaccin ekoki kondimama.
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
Mosala esalamaki liboso mpóna SRAS-CoV ezo salamela na ntína ete SRAS-CoV na SRAS-CoV-2 nionso mibale ezo salela moyambi ACE2 mpóna kokota na bacellula ya moto.
There are three vaccination strategies being investigated.
Bastrategie ya vaccinasio ezali misato bazo lukela.
First, researchers aim to build a whole virus vaccine.
Ya yambo, bakundoli batie likanisi na botongi ya vaccin ya virusi mobimba.
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
Bosáleli ya virusi ya boye, ezala ya koningana to ya kokufa, eluki ko bimisa noki eyano ya Immunité ya nzoto ya moto ya kpokoso ya sika na COVID-19.
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
Strategie ya mibale, vaccin ya sous-unité, ezo luka ebimisa vaccin óyo ekosensitisé systemi ya Immunité na basous-unité ya solo ya virusi.
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
Na cas ya SRAS-CoV-2, bokundoli ya boye etie miso na baproteine ya spicule-S óyo esalisaka virusi ekota nakati ya moyambi ya enzyme ACE2 .
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
Strategie ya misato ezali óyo ya bavaccin ya acide nucleiki (DNA to bavaccin RNA, tekiniki ya sika mpóna kobongisa vaccinasio).
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
Ba vaccin bazo experimenté na bosaleli ya ba strategie yango esengeli ezala tesité mpóna securité pe bolamo ya bosaleli. Na16 Mars 2020, momekano ya yambo ya vaccin na cliniki ebandaki na bato minei ya bolingi na Seattle.
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
Vaccin eza na kati nango code genetiki ya bokono te basali kopi uta na virusi mutu epesaka bokono. Bobakisi ya bokasi ezo dépendre na anticorps esi ekaniselami na esika ya etumba eko kozala mpóna bokolisi ya vaccin ya SRAS-COV-2, kasi óyo eza naino likambo ya koswanela.
There are more than 300 active clinical trials underway as of April 2020.
Mimekano ya cliniki eza kosalema eza koleka 300 na sanza ya Avril 2020.
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
Mimekano sambo mizali koyekola batraitement óyo esi endimami mpóna malaria, tia nakati minei eza koyekola hydroxychloroquine to chloroquine.
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Bakisi ya antivirusi babongeseli ntina mosusu esali ngambo ya nyonso ya mayekoli ya ba Chinois, na ba phase III libwa ya mimekano na remdesivir ezo salama na bikolo ebele biye bikopesa lapolo na suka Avril.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Botalololi ya dynaimiki ya bokolisi na cliniki ya vaccin mpóna COVID-19 na kisi ekoki kondimama esi ebelemi na Avril 2020.Bakisi ya antivirusi ebele óyo esi esalama ezali koyekolama mpóna traitement ya COVID-19, tia nakati remdesivir, chloroquine pe hydroxychloroquine, lopinavir/ritonavir pe lopinavir/ritonavir esangana na interferon beta.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Elembo ebandaki komonana mpóna bolamu ya remdesivir, na Mars 2020.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
Bobakisi ya bolamu ya cliniki emonanaki na bato ya bokono bazwaki traitement ya boyóki mawa remdesivir.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Mimekano ya cliniki Phase III mizali kosalema na E.U., Chine pe Italie. Chloroquine, óyo basalelaki liboso mpóna kotraité malaria, eyekolamaki na Chine na Février 2020, na mabimi ma yambo.
However, there are calls for peer review of the research.
Kási, mabéngi mazali ete bato ya mayele batalolola mabimi ma makundoli.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Bakónzi ya Santé ya Korea pe Chine bazo tinda basalela chloroquine.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Kási, Institut ya Virologie ya Wuhan, ntango bazo tinda doze ya gamma moko mokolo-na-mokolo, bayebisi ete mibale ya doze yango ezali mabe mingi penza pe ekoki koboma.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
Na 28 Mars2020, FDA abimisaki ndíngisa ya bosaleli ya bombango mpóna hydroxychloroquine pe chloroquine na bobombi sekelé ya minganga miye mizali kotraité babeli ya COVID-19.Edition 7 ya bato ya Chine ebakisaki lisusu interferon, ribavirin to umifenovir mpóna koboma COVID-19.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Badonnée ya yambo ezo lakisa ete ba doze ya likolo ya ribavirin ezali na ntina monene mpóna kobeta SRAS-CoV-2 in vitro.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Nitazoxanide esi etindami mpóna boyekolii in vivo ekolanda sima ya bolakisi concentrasio ya moke ya inhibisio ya SRAS-CoV-2. Mayekoli malakisi ete bokotisi ya specule ya proteine ya ebandeli na bosaleli ya protéase ya transmembrane serine 2 (TMPRSS2) ezali na ntina monene penza mpóna bokoti ya SRAS-CoV-2 na nzela ya interacsio na moyambi ya ACE2.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Mayekoli ya chloroquine na hydroxychloroquine na to kozanga azithromycine ezali na bandelo ya makasi óyo eye kosala ete lisanga ya bato ya bakisi babóya koyamba ba thérapie kozanga liyekoli ya bolandi. Oseltamivir ebetaka nango SRAS-CoV-2 in vitro te pe eza na mosala te óyo eyebani na traitement ya COVID-19.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Tempete ya cytokine eko kozala pasi mabe ya etape ya suka ya COVID-19 ya makasi.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Elembo ezo monana ete hydroxychloroquine eko kozala na ba propriété ya kopekisa tempete cytokine.Tocilizumab esi ekotisami na masungi ya traitement na Comission Nationale ya Santé ya Chine sima ya bosilisi ya liyekoli ya moke.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Bazali kosala sik’óyo phase 2 ya tesite non-randomisé na niveau ya ekolo mobimba na Italie sima ya bolakisi bambuma malamu na bato bazali na bokono ya makasi.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Bosangisi yango na tesite ya makila ya serum ferritin mpóna ko yebela, esalami mpóna kopekisa bokoli, yango mutu ekaniselami kozala esika liwa ewutaka mpóna kamwa ndámbo ya bato bazwi kpokoso.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Moyambi ya tembe interleukin-6 endimamaka na FDA ose ya malandeli ya mayekoli masalamaka liboso mpóna traitement ya syndrome ya botiki steroide cytokine refractaire esalama na ntina ekesana, cellula ya therapi CAR T, na 2017.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Na mokolo ya lelo, elembo ya randomisé pe controlé ezali te mpóna bondimi ete tocilizumab eza kisi ya solo na CRS.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Bolekisi ya ba anticorps bapurifiaki pe bacocentraki óyo ewuti na systeme immune ya bato babikaki na bokono ya COVID-19 na nzoto ya baye bazali na mposa na yango ezo landama bokundoli mpo ezala methodi ezanga vaccin na immunizasio passifi.
This strategy was tried for SARS with inconclusive results.
Esaleli ya boye bamekaki yango kasi ebotaki mbuma te.
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
Neutralizasio ya virusi ezali nzela bazo kanisela ekozala mosala óyo therapi ya ba anticorps passifi ekokoka komediaté bobateli ya tembe na SRAS-CoV-2.
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
Banzela mosusu kasi, ndakisa cytotoxicité pe/to phagocytose ya cellula dependant na anticorps eko kosala.
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
Ba ndenge mosusu ya therapi passive ya anticorps, ndakisa, bosaleli ya ba anticorps monocloniki basali na masini, ezali kokolisama.
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
Mobombisi ya serum ya babeli bazo bika na bokono, mutu ezalaka na ndambo ya makila ya mayi ewuti na bato babiki pe eza na ba anticorps specifiki na virusi yango, ekoki ebákisama mpóna bokaboli yango na bombango.
Coronavirus diseases, a group of closely related syndromes
Mabela ya coronavirusi, liboke ya basyndrome óyo ekangana kamwa mingi
Li Wenliang, a doctor at Central Hospital of Wuhan, who later contracted and died of COVID-19 after raising awareness of the spread of the virus.
Li Wenliang, monganga ya Lopitalo Centrale ya Wuhan, ye mutu azwaki kpokoso ya COVID-19 na suka akufaki sima ya bomatisi boyebi ya bopalangani ya virusi yango.